<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445679</url>
  </required_header>
  <id_info>
    <org_study_id>3151A1-336</org_study_id>
    <nct_id>NCT00445679</nct_id>
  </id_info>
  <brief_title>Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Paroxetine-referenced, Parallel-group Study to Evaluate the Safety, Efficacy, and Tolerability of 3 Fixed Doses (50mg, 100mg, AND 200mg) of Desvenlafaxine Succinate Sustained-release Tablets in Adult Outpatients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability and efficacy of desvenlafaxine succinate
      sustained release (DVS SR) in subjects with major depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to investigate the efficacy, safety and tolerability
      of desvenlafaxine succinate sustained release (DVS SR) in Chinese, Taiwanese, South Korean,
      and Indian subjects with major depressive disorder (MDD) receiving daily doses of 50 mg, 100
      mg, or 200 mg. The secondary objective is to obtain additional information regarding the
      efficacy of DVS SR in subjects with MDD receiving daily doses of 50 mg, 100 mg, or 200 mg.
      Additional objectives include obtaining general and functional quality of life outcome data.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17)</measure>
    <time_frame>8 weeks</time_frame>
    <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Scale-Improvement (CGI-I) Scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale, the clinician rates how much the subject's illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions Scale-Severity of Illness (CGI-S) Scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>CGI-S is a global rating scale that measures the severity of a subject's disease. Using a 7-point scale, the clinician rates the severity of the patient's mental illness at the time of the assessment, relative to the clinician's experience with subjects who have the same diagnosis (1= normal, not at all ill; 7= among the most extremely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery and Asberg Depression Rating Scale (MADRS) Total Score Mean Change From Baseline</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale-pain Intensity (VAS-PI) Score Mean Change From Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>The VAS-PI is a self-rated visual analog scale for the assessment of pain. Scores on the VAS-PI range from 0 (no pain) to 10 (worst possible pain). A decrease in VAS-PI overall scores indicates a subject's assessment of an improvement in pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Depression, 6-item (HAM-D6) Score Mean Change From Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>HAM-D6: standardized, clinician-administered rating scale is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 (0=none/absent to 2=most severe) and all others are scored 0 to 4 (0=none/absent to 4=most severe). Total score ranges from 0 to 22; higher score indicates more depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covi Anxiety Scale Score Mean Change From Baseline</measure>
    <time_frame>8 weeks</time_frame>
    <description>Covi anxiety scale measures the severity of anxiety symptoms on 3 items: verbal report, behavior and somatic complaints. Each dimension is assessed using a 5-point scale: 1 = not at all, 2 = somewhat, 3 = moderately, 4 = considerably, 5 = Very much. Total score ranges from 3 to 15; higher score indicates more anxiety.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">807</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DVS SR 50mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DVS SR 100mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DVS SR 200mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paroxetine 20mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DVS SR</intervention_name>
    <description>Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine</intervention_name>
    <description>20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          1. Outpatient men and women at least 18 years of age.

          2. Have a primary diagnosis of MDD based on the criteria in the Diagnostic and
             Statistical Manual of Mental Disorders, 4th edition (DSM IV), single or recurrent
             episode, without psychotic features.

          3. Have a HAM D17 total score â‰¥20 at the screening and baseline (study day 1) visit.

        Primary Exclusion Criteria:

          1. Treatment with DVS SR at any time in the past.

          2. Significant risk of suicide based on clinical judgment, including common suicidal
             thoughts and suicide having been considered as a possible solution even without
             specific plans or intent.

          3. Any unstable hepatic, renal, pulmonary, cardiovascular (including uncontrolled
             hypertension), ophthalmologic, neurologic, or any other medical condition that might
             confound the study or put the subject at greater risk during study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For China: medinfo@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangdong Province</city>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hunan Province</city>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jiangsu Province</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanxi Province</city>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sichuan Province</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yunnan Province</city>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zhejiang Province</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Andhra Pradesh</city>
        <zip>500 038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Andhra Pradesh</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Andhra Pradesh</city>
        <zip>517 507</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Andhra Pradesh</city>
        <zip>530 002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gujarat</city>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gujarat</city>
        <zip>380013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karnataka</city>
        <zip>575 001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karnataka</city>
        <zip>575018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maharashtra</city>
        <zip>400 012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maharashtra</city>
        <zip>400 026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maharashtra</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai Maharashtra</city>
        <zip>H19400 022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Punjab</city>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uttar Pradesh</city>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>140-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>150-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chang-Hua</city>
        <zip>ROC 500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>KaoHsiung</city>
        <zip>ROC 80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>ROC 100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>ROC 111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>ROC 112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>ROC 114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>ROC 220</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2007</study_first_submitted>
  <study_first_submitted_qc>March 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <results_first_submitted>February 26, 2010</results_first_submitted>
  <results_first_submitted_qc>October 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2013</results_first_posted>
  <last_update_submitted>October 8, 2013</last_update_submitted>
  <last_update_submitted_qc>October 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>major depressive disorder</keyword>
  <keyword>MDD</keyword>
  <keyword>depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited in China, India, South Korea and Taiwan from July 2007 to December 2008.</recruitment_details>
      <pre_assignment_details>After a 4 to 21 day screening period, eligible subjects were treated for up to 8 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DVS SR 50</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
        </group>
        <group group_id="P2">
          <title>DVS SR 100</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
        </group>
        <group group_id="P3">
          <title>DVS SR 200</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
        </group>
        <group group_id="P4">
          <title>Paroxetine 20</title>
          <description>Paroxetine 20 mg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="205"/>
                <participants group_id="P4" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="139"/>
                <participants group_id="P4" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Informed Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DVS SR 50</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
        </group>
        <group group_id="B2">
          <title>DVS SR 100</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
        </group>
        <group group_id="B3">
          <title>DVS SR 200</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
        </group>
        <group group_id="B4">
          <title>Paroxetine 20</title>
          <description>Paroxetine 20 mg/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="203"/>
            <count group_id="B2" value="203"/>
            <count group_id="B3" value="205"/>
            <count group_id="B4" value="196"/>
            <count group_id="B5" value="807"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.63" spread="12.96"/>
                    <measurement group_id="B2" value="39.26" spread="13.22"/>
                    <measurement group_id="B3" value="39.26" spread="14.69"/>
                    <measurement group_id="B4" value="38.27" spread="13.22"/>
                    <measurement group_id="B5" value="38.86" spread="13.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="117"/>
                    <measurement group_id="B5" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17)</title>
        <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
        <time_frame>8 weeks</time_frame>
        <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 50</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 100</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 200</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Paroxetine 20</title>
            <description>Paroxetine 20 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders With a 50% or Greater Decrease From Baseline on the Hamilton Rating Scale for Depression, 17-item (HAM-D17)</title>
          <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.</description>
          <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation.</population>
          <units>percentage of responders</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority to paroxetine was declared if the lower limit of the 95% two-sided confidence interval for the difference in responders is greater than or equal to -9 percentage points.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-3.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.62</ci_lower_limit>
            <ci_upper_limit>6.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority to paroxetine was declared if the lower limit of the 95% two-sided confidence interval for the difference in responders is greater than or equal to -9 percentage points.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.50</ci_lower_limit>
            <ci_upper_limit>10.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority to paroxetine was declared if the lower limit of the 95% two-sided confidence interval for the difference in responders is greater than or equal to -9 percentage points.</non_inferiority_desc>
            <param_type>Difference</param_type>
            <param_value>-2.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.68</ci_lower_limit>
            <ci_upper_limit>7.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions Scaleâ€“Improvement (CGI-I) Scores</title>
        <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale, the clinician rates how much the subject's illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse).</description>
        <time_frame>8 weeks</time_frame>
        <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 50</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 100</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 200</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Paroxetine 20</title>
            <description>Paroxetine 20 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions Scaleâ€“Improvement (CGI-I) Scores</title>
          <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale, the clinician rates how much the subject's illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse).</description>
          <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="196"/>
                <count group_id="O4" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Final - Score 1 (Very much improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 2 (Much improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 3 (Minimally improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 4 (No change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 5 (Minimally worse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 6 (Much worse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 7 (Very Much worse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final on-therapy population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.714</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final on-therapy population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.653</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final on-therapy population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.881</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions Scaleâ€“Severity of Illness (CGI-S) Scores</title>
        <description>CGI-S is a global rating scale that measures the severity of a subjectâ€™s disease. Using a 7-point scale, the clinician rates the severity of the patientâ€™s mental illness at the time of the assessment, relative to the clinicianâ€™s experience with subjects who have the same diagnosis (1= normal, not at all ill; 7= among the most extremely ill).</description>
        <time_frame>8 weeks</time_frame>
        <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 50</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 100</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 200</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Paroxetine 20</title>
            <description>Paroxetine 20 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impressions Scaleâ€“Severity of Illness (CGI-S) Scores</title>
          <description>CGI-S is a global rating scale that measures the severity of a subjectâ€™s disease. Using a 7-point scale, the clinician rates the severity of the patientâ€™s mental illness at the time of the assessment, relative to the clinicianâ€™s experience with subjects who have the same diagnosis (1= normal, not at all ill; 7= among the most extremely ill).</description>
          <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Final - Score 1 (Normal, not at all ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 2 (Borderline mentally ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 3 (Mildly ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 4 (Moderately ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 5 (Markedly ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 6 (Severely ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final - Score 7 (Among the most extremely ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final on-therapy population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.450</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final on-therapy population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.452</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Final on-therapy population</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.850</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery and Asberg Depression Rating Scale (MADRS) Total Score Mean Change From Baseline</title>
        <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 50</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 100</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 200</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Paroxetine 20</title>
            <description>Paroxetine 20 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery and Asberg Depression Rating Scale (MADRS) Total Score Mean Change From Baseline</title>
          <description>Measures the overall severity of depressive symptoms. The MADRS has a 10-item checklist. Items are rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).</description>
          <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.84" lower_limit="-18.37" upper_limit="-15.31"/>
                    <measurement group_id="O2" value="-17.84" lower_limit="-19.37" upper_limit="-16.31"/>
                    <measurement group_id="O3" value="-16.81" lower_limit="-18.43" upper_limit="-15.20"/>
                    <measurement group_id="O4" value="-16.54" lower_limit="-18.08" upper_limit="-15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale-pain Intensity (VAS-PI) Score Mean Change From Baseline</title>
        <description>The VAS-PI is a self-rated visual analog scale for the assessment of pain. Scores on the VAS-PI range from 0 (no pain) to 10 (worst possible pain). A decrease in VAS-PI overall scores indicates a subjectâ€™s assessment of an improvement in pain.</description>
        <time_frame>8 weeks</time_frame>
        <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 50</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 100</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 200</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Paroxetine 20</title>
            <description>Paroxetine 20 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale-pain Intensity (VAS-PI) Score Mean Change From Baseline</title>
          <description>The VAS-PI is a self-rated visual analog scale for the assessment of pain. Scores on the VAS-PI range from 0 (no pain) to 10 (worst possible pain). A decrease in VAS-PI overall scores indicates a subjectâ€™s assessment of an improvement in pain.</description>
          <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="191"/>
                <count group_id="O4" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.69" lower_limit="-15.10" upper_limit="-8.27"/>
                    <measurement group_id="O2" value="-10.00" lower_limit="-13.75" upper_limit="-6.26"/>
                    <measurement group_id="O3" value="-9.10" lower_limit="-12.75" upper_limit="-5.45"/>
                    <measurement group_id="O4" value="-9.52" lower_limit="-12.40" upper_limit="-6.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Rating Scale for Depression, 6-item (HAM-D6) Score Mean Change From Baseline</title>
        <description>HAM-D6: standardized, clinician-administered rating scale is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 (0=none/absent to 2=most severe) and all others are scored 0 to 4 (0=none/absent to 4=most severe). Total score ranges from 0 to 22; higher score indicates more depression.</description>
        <time_frame>8 weeks</time_frame>
        <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 50</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 100</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 200</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Paroxetine 20</title>
            <description>Paroxetine 20 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression, 6-item (HAM-D6) Score Mean Change From Baseline</title>
          <description>HAM-D6: standardized, clinician-administered rating scale is a subset of the HAM-D17 that assesses 6 items associated with major depression. The scale uses HAM-D17 items 1, 2, 7, 8, 10 and 13. Item 13 is scored 0 to 2 (0=none/absent to 2=most severe) and all others are scored 0 to 4 (0=none/absent to 4=most severe). Total score ranges from 0 to 22; higher score indicates more depression.</description>
          <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.50" lower_limit="-7.08" upper_limit="-5.92"/>
                    <measurement group_id="O2" value="-6.51" lower_limit="-7.06" upper_limit="-5.95"/>
                    <measurement group_id="O3" value="-6.42" lower_limit="-7.03" upper_limit="-5.82"/>
                    <measurement group_id="O4" value="-6.58" lower_limit="-7.15" upper_limit="-6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Covi Anxiety Scale Score Mean Change From Baseline</title>
        <description>Covi anxiety scale measures the severity of anxiety symptoms on 3 items: verbal report, behavior and somatic complaints. Each dimension is assessed using a 5-point scale: 1 = not at all, 2 = somewhat, 3 = moderately, 4 = considerably, 5 = Very much. Total score ranges from 3 to 15; higher score indicates more anxiety.</description>
        <time_frame>8 weeks</time_frame>
        <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR 50</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
          </group>
          <group group_id="O2">
            <title>DVS SR 100</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
          </group>
          <group group_id="O3">
            <title>DVS SR 200</title>
            <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
          </group>
          <group group_id="O4">
            <title>Paroxetine 20</title>
            <description>Paroxetine 20 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Covi Anxiety Scale Score Mean Change From Baseline</title>
          <description>Covi anxiety scale measures the severity of anxiety symptoms on 3 items: verbal report, behavior and somatic complaints. Each dimension is assessed using a 5-point scale: 1 = not at all, 2 = somewhat, 3 = moderately, 4 = considerably, 5 = Very much. Total score ranges from 3 to 15; higher score indicates more anxiety.</description>
          <population>The intent-to-treat (ITT) population included all subjects randomly assigned to treatment who had a baseline HAM-D17 evaluation, took at least 1 dose of double-blind test article, and had at least 1 postbaseline HAM-D17 evaluation. Number of participants analyzed reflects the final on-therapy population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="192"/>
                <count group_id="O4" value="185"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.23" lower_limit="-1.47" upper_limit="-0.99"/>
                    <measurement group_id="O2" value="-1.28" lower_limit="-1.54" upper_limit="-1.03"/>
                    <measurement group_id="O3" value="-1.17" lower_limit="-1.44" upper_limit="-0.89"/>
                    <measurement group_id="O4" value="-1.24" lower_limit="-1.49" upper_limit="-1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DVS SR 50</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg/day</description>
        </group>
        <group group_id="E2">
          <title>DVS SR 100</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 100 mg/day</description>
        </group>
        <group group_id="E3">
          <title>DVS SR 200</title>
          <description>Desvenlafaxine Succinate Sustained-Release (DVS SR) 200 mg/day</description>
        </group>
        <group group_id="E4">
          <title>Paroxetine 20</title>
          <description>Paroxetine 20 mg/day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pituitary tumor benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Suicidal behavior</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Major Depressive Disorder worsening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="140" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="134" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="205"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

